Publicado 31/05/2014 15:06
- Comunicado -

Investigational Drug AZD9291 Shows Clinical Responses in Patients With Advanced NSCLC Who Have Previously Failed on Esta

In the ongoing Phase I study, AZD9291 has shown early evidence of activity as a once-daily monotherapy with clinical responses observed in an EGFRm+ population of patients with NSCLC who have previously failed on EGFR TKIs and also in patients with the T790M resistance mutation[1].

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: http://www.astrazeneca.com.

        
        CONTACTS

        Media Enquiries

        Esra Erkal-Paler
        +44-20-7604-8030 (UK/Global)

        Vanessa Rhodes
        +44-20-7604-8037 (UK/Global)

        Ayesha Bharmal
        +44-20-7604-8034 (UK/Global)

        Michele Meixell
        +1-302-885-2677 (US)

        Jacob Lund
        +46-8-553-260-20 (Sweden)

        Investor Enquiries

        Karl Hard
        +44-20-7604-8123
        mob: +44-7789-654364

        Colleen Proctor
        +1-302-886-1842
        mob: +1-302-357-4882

        Anthony Brown
        +44-20-7604-8067
        mob: +44-7585-404943

        Jens Lindberg
        +44-20-7604-8414
        mob: +44-7557-319729

1. Jänne PA, et al. Clinical activity of the mutant selective EGFR Inhibitor AZD9291 in patients (pts) with EGFR inhibitor resistant non-small cell lung cancer (NSCLC). Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA; 30 May - 3 June 2014. Abstract available at: http://abstracts.asco.org/144/AbstView_1.... Data cited is included in final data presentation on 31 May 2014: Session: Targeting EGFR: The Next 10 Years; Clinical Science Symposium

2. National Institutes of Health. AZD9291 First Time In Patients Ascending Dose Study (AURA). Available at: http://www.clinicaltrials.gov/ct2/show/N.... Accessed April 2014.

3. Szumera-Cieckiewicz A, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol. 2013;6:2800-12.

4. Keedy VL, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29:2121-7.

5. Ellison G, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66:79-89.

6. Sharma SV, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.

7. Mok TS, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009;361:947-957.

8. Rosell R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology. 2012;13:239-246.

9. Yu H, et al. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res. 2013:19:8 2240-2247

10. Ranson M, et al. AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFRm+) and resistance (T790M) mutations in advanced NSCLC. J Thorac Oncol. 2013;8(Suppl.2):S389 (abstract MO21.12).

11. Pollack M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer. 2008;8:915-928.

12. Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinogenesis. 2013;12:1 22-45.

Comunicados

Si quieres mejorar el posicionamiento online de tu marca, ahora puedes publicar tus notas de prensa o comunicados de empresa en la sección de Comunicados de europa press

Si necesitas asesoramiento en comunicación, redacción de tus notas de prensa o ampliar la difusión de tu comunicado más allá de la página web de europa press, ponte en contacto con nosotros en comunicacion@europapress.es o en el teléfono 913592600